Zantac® and Cancer Causing NDMA
Written By: Peter Soares
Ranitidine, approved by the FDA under the brand name Zantac®, is a medication commonly used to treat acid reflux. An independent study conducted by Valisure, an online pharmacy and laboratory company, discovered a link between Zantac® to the carcinogen N- nitrosodimethylamine (NDMA). The study indicated an “inherent instability” of the ranitidine molecule resulted in the formation of NDMA. Many ranitidine-containing medications, such as Zantac®, may generate high levels of NDMA when metabolized by the body.
Although the FDA has yet to order a recall of the drug, many organizations are voluntarily recalling ranitidine products:
- October 18, 2019 – Drug maker Sanofi voluntarily recalls Zantac® OTC (over-the-counter) in the U.S. and Canada.
- September 28, 2019 – CVS Pharmacy suspends the sale of all Zantac® brand and CVS Health branded ranitidine products until further notice.
- September 25, 2019 – Apotex Corp. issues voluntary nationwide recall of ranitidine tablets due to the potential for detection of NDMA. Apotex Corp. supplied these tablets to Rite Aid, Walgreens, and Walmart.
The FDA has stated “NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on laboratory tests.” Cancers linked to NDMA exposure include:
- Bladder Cancer
- Colorectal Cancer
- Esophageal Cancer
- Liver Cancer
- Multiple Myeloma
- Non-Hodgkin’s Lymphoma
- Pancreatic Cancer
- Prostate Cancer
- Small Intestine Cancer
- Stomach Cancer
Regular Use of Zantac and Development of Cancer
If you or a loved one developed cancer after regular use of Zantac for a period of weeks or months, you may be entitled to compensation. Our attorneys at Rheingold Giuffra Ruffo & Plotkin LLP are currently speaking with individuals who may have developed cancer as a result of regular Zantac use. If you believe you have a Zantac lawsuit and wish to discuss your legal options, please call our New York office location at (888) 260-0473.